1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Brawn Biotech Limited

Brawn Biotech Limited

BBSE:BRAWN
25.40
INR
0.00
(0.00%)
2.93EPS
7.01P/E
61.51MMarket Cap
Brawn Biotech Limited
BSE:BRAWN
(Bombay Stock Exchange)

Recent

price

25.40

P/E

ratio

7.01

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
3.18
53.72
47.76
104.48
128.81
156.26
198.67
183.37
217.06
165.24
116.52
26.51
68.91
51.76
39.91
48.43
58.77
Revenue per Share
1.61
1.37
0.08
1.5
0.95
3.17
4.64
4.27
4.44
1.97
-1.84
-5.48
-2.89
-4.16
-5.8
3.14
2.93
Basic EPS, GAAP
0.07
0.89
- -
- -
0.77
0.17
4.44
-5.15
0.7
-0.32
0.11
0.63
1.06
-0.09
0.16
0.37
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.15
13.86
14.2
15.12
16.46
19.62
23.06
25.43
28.85
30.87
29.31
24.07
21.03
16.88
11.21
14.46
- -
Book Value per Share
13.15
13.86
14.2
15.12
16.46
19.62
23.06
25.43
28.85
30.87
29.31
24.07
21.03
16.88
11.21
14.46
- -
Tangible Book Value per Share
3
3
3
2
3
3
3
3
3
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
10
161
145
245
386
469
596
550
651
496
350
80
207
155
120
145
173
Sales/Revenue/Turnover
12.46
2.56
1.73
2.65
1.47
3.11
6.54
3.51
2.19
1.56
-1.72
-25.88
-1.99
-10.07
-15.75
-3.05
-3.35
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Depreciation Expense
5
4
- -
4
3
9
14
13
13
6
-6
-16
-9
-12
-17
9
9
Net Income, GAAP
6.96
- -
88.45
38.46
40.57
27.22
20.69
34.65
26.17
27.87
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
50.53
2.56
0.16
1.44
0.74
2.03
2.34
2.33
2.05
1.19
-1.57
-20.67
-4.2
-8.03
-14.53
6.47
4.98
Profit Margin (%)
31
38
45
9
19
30
66
70
80
83
78
59
54
66
82
19
- -
Working Capital
- -
3
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
39
42
43
45
49
59
69
76
87
93
88
72
63
51
34
43
- -
Total Equity
2.96
9.81
0.5
7.52
5.99
16.06
17.79
13.48
9.64
5.1
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
13.03
10.82
0.5
7.52
6.93
17.55
22.1
17.95
16.69
6.81
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
13
10.17
0.55
7.95
6
17.55
21.76
17.62
16.37
6.6
-6.1
-20.53
-12.83
-21.93
-41.3
24.43
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
65
63
62

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
171
- -
Cash, Cash Equivalents & STI
- -
16
- -
Accounts Receivable, Net
- -
35
- -
Inventories
- -
101
- -
Total Current Liabilities
- -
152
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.16%
-10.96%
29.06%
Free Cash Flow
211.89%
55.13%
135.85%
Net Income, GAAP
-12.55%
16.11%
-154.06%
Sales/Revenue/Turnover
4.07%
11.25%
21.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
41
33
38
58
120
2026
58
49
43
20
145
2027
61
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-1.83
-0.96
-1.44
4.34
-5.8
2026
0.89
0.25
0.17
1.95
3.14
2027
0.52
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Brawn Biotech Limited is an India-based healthcare and pharmaceutical company engaged in the marketing, trading, distribution, and export of finished pharmaceutical formulations and healthcare products. Founded in 1985 and formerly known as Brawn Pharmaceuticals Limited, the company is headquartered in New Delhi, India, with corporate operations based in Gurugram, Haryana. Brawn Biotech operates within the pharmaceutical trading and healthcare segment, supplying a diversified portfolio of generic and branded formulations across domestic and international markets. The company offers a broad range of products across multiple therapeutic categories, including antibacterials and antibiotics, such as cephalosporins and broad-spectrum antimicrobial agents; cardiovascular agents and antidiabetic therapies; analgesics, antipyretics, and anti-inflammatory formulations, including topical pain-relief ointments and gels; gastrointestinal drugs, laxatives, and antacids; antifungal and dermatological treatments for skin care disorders; central nervous system agents, anticonvulsants, and antipsychotic therapies; respiratory medications and antiasthmatic preparations; antimalarial formulations; and nutritional supplements, hematinics, and multivitamin preparations. These offerings are distributed across varied dosage forms, including solid oral tablets, hard and soft gelatin capsules, oral liquids, dry syrups, sterile injectables, topical creams, and medicinal gels. In recent developments, Brawn Biotech has focused on expanding its international market presence across emerging regions in Asia, Africa, and Latin America through continuous participation in global healthcare forums and industry exhibitions such as CPHI and MEDICA. Operationally, the company has optimized its wholesale formulation distribution network, streamlined its supply chain management, enhanced corporate governance and equity compliance under revised capital market frameworks, and maintained a conservative, virtually debt-free capital structure to support its ongoing commercial expansion and product distribution activities.